TPThesla Palanee-Phillips

Thesla Palanee-Phillips

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thesla Palanee-Phillips has a total of 267 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ethical and emotional complexity of verbal autopsy implementation in South Africa: a preliminary trauma-informed practice framework

    by Lucia D’AMbruoso, Thesla Palanee-Phillips, Alex Hinga, Phumla Sibiya, Danisile Sambo, Krishnaveni Reddy, André Rose

  • Open Access

    Factors associated with women’s preference for an over-encapsulated dual prevention pill: findings from South Africa and Zimbabwe

    by Sanyukta Mathur, Marlena G. Plagianos, Barbara A. Friedland, Irene V. Bruce, J. Brady Burnett-Zieman, Adlight Dandadzi, Petina Musara, Nkosiphile Ndlovu, Natasha Sedze, Siyanda Tenza, et al.

    Background: A dual prevention pill (DPP) for co-delivery of pregnancy and HIV prevention is currently in development and will offer an alternative to taking two separate products. We examined behavioral, interpersonal partnership, social, and structural correlates of preferences for an over-encapsulated DPP (as a proxy for the co-formulated product under development/testing, consisting of oral contraceptive pill and oral HIV prevention pre-exposure prophylaxis (PrEP) pill) among women and adolescent girls in South Africa and Zimbabwe to inform DPP introduction and counseling strategies. Methods: This secondary analysis used data from two clinical crossover trials that compared the acceptability, adherence, and preference for the over-encapsulated DPP versus separate PrEP and oral contraceptives. HIV-negative, non-pregnant cisgender women were enrolled in Johannesburg, South Africa ( n = 96, ages 18–40) and Harare, Zimbabwe ( n = 30, ages 16–24). Participants were randomized 1:1 to use either DPP or two separate pills for three 28-day cycles, then switched. Preferences were measured at the end of crossover and via exit in-depth interviews. Results: The mean age was 27 years in South Africa and 19 years for Zimbabwe. Most participants had completed secondary school, while childbearing experience was more common in Zimbabwe (97%) than in South Africa (74%). Pregnancy prevention was highly valued in both sites (~ 90%), but Zimbabwean participants voiced greater concern about HIV. DPP preference was higher in Zimbabwe (62%) than in South Africa (39%). In South Africa, bivariate analysis showed that DPP preference was associated with behavioral factors (no anal sex experience, ever experience of sexual violence, relationship conflict, and transactional relationships/sex) and product characteristics (ease of use, side effects), although only anal sex and relationship control remained significant in the multivariable model. In Zimbabwe, concern about HIV acquisition (but in the opposite direction), interpersonal power, structural factors (i.e., more food insecurity and less housing insecurity), and ease of use were associated with DPP preference in bivariate analyses (no multivariable analysis was possible). Qualitative interviews highlighted the DPP’s simplicity as a key advantage over two separate pills, though participants desired a smaller DPP and more discreet packaging to reduce stigma and ease use. Conclusions: While women in both countries value integrated HIV and pregnancy prevention, distinct behavioral and social factors, and product attributes influence DPP preference. Tailoring DPP introduction and support strategies to address specific challenges—such as relationship dynamics and product usability—may support acceptability and informed choice of dual prevention strategies. Trial registration: ClinicalTrials.gov, Zimbabwe: NCT04778514 (02/25/2021); South Africa: NCT04778527 (02/25/2021).

  • Open Access

    Development of a Self-administered Sexual Behavior Assessment Tool to Facilitate Self-reflection by Young Women in South Africa About HIV/STI Risk

    by Krishnaveni Reddy, Jiaying Hao, Merusha Govindasami, Nomasonto Matswake, Busisiwe Jiane, Lindsay Kew, Nkosiphile Ndlovu, Reginah Stuurman, Hlengiwe Mposula, Renee Heffron, et al.

    Self-assessment of sexual behavior may empower adolescent girls and young women (AGYW) to reflect on HIV/STI risk and adopt prevention strategies. We developed a web-based sexual behavior self-assessment tool providing real-time feedback based on a numeric score and examined associations of scores with STI detection and HIV pre-exposure prophylaxis (PrEP) initiation among AGYW in South Africa. The tool was implemented as part of PALESA, a pilot randomized trial which followed up 55 sexually-active AGYW (16–20 years) for six months in Johannesburg between June 2023 and May 2024. Participants received monthly links to the tool, monthly oral PrEP offering and quarterly chlamydia, gonorrhea, and trichomoniasis testing. Multivariable generalized linear mixed-effects models and survival models assessed associations between participants’ scores and STI detection and PrEP restart; interrupted time series analysis examined score changes around PrEP initiation. Tool completion rate was high (94.8%). Frequently reported items included older partners (38.4%), vaginal STI symptoms (26.3%), new sexual relationships (20.0%), multiple partners (18.9%) and partner distrust about STI symptom experiences (17%). Higher scores were associated with increased odds of STI detection (adjusted odds ratio: 2.61, 95% CI: 1.46–4.68) but not significantly with PrEP initiation (adjusted hazard ratio: 1.43, 95% CI: 0.56–3.63). Among participants who restarted PrEP, scores decreased by 0.47 points per month before PrEP restart ( p = 0.002) and remained stable afterward ( p = 0.39). Our findings demonstrate this tool as feasible to implement among AGYW with potential to support self-reflection and awareness of HIV/STI risk. Larger studies are warranted to fully evaluate its utility.

  • Open Access

    Mental health, HIV and healthcare-related discrimination among young sexual minority men in Kenya: implications for integrated care and stigma reduction

    by Samuel W. Mwaniki, Richard M. Kilonzo, Peter M. Kaberia, Carlos K. Cheruiyot, Walter M. Nyagah, Humphrey K. Rop, Adrian D. Smith, Thesla Palanee-Phillips

    Mental health conditions among young sexual minority men (YSMM) are a growing public health concern, yet they are understudied in sub-Saharan African settings. We aimed to estimate the prevalence of depressive and anxiety symptoms, and associated factors among YSMM in Kenya. Between February and March 2021, we conducted a cross-sectional bio-behavioral survey among YSMM aged 18 years or older and enrolled in tertiary academic institutions in Nairobi, using respondent-driven sampling. Participants completed an electronically self-administered demographic and behavioral questionnaire on REDCap. Depressive and anxiety symptoms were assessed using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) tools respectively, with scores equal to or greater than 10 indicating moderate-to-severe symptoms. HIV antibody testing followed Kenyan national guidelines. Principal component analysis was used to derive stigma-related domains, and multivariate logistic regression identified factors associated with outcomes. Data analysis was done using Stata v.17 software. Among 242 participants, median age was 21 years (IQR 19-23). Prevalence of depressive, anxiety, co-occurring depressive/anxiety symptoms and HIV were: 23.7% (95% CI: 18.4-29.5), 16.9% (95% CI: 12.4-22.3), 12.4% (95% CI: 8.5-17.2) and 8.3% (95% CI: 5.1-12.5), respectively. Factors independently associated with depressive symptoms were: living with HIV (AOR: 4.88, 95% CI: 1.18-20.18, p = 0.029), moderate-to-severe anxiety symptoms (AOR: 25.63, 95% CI: 8.58-76.61, p<0.001), healthcare-related discrimination (AOR: 1.56, 95% CI: 1.07-2.28, p = 0.020) and early years of study (AOR: 2.79, 95% CI: 1.09-7.15, p = 0.033). Factors independently associated with anxiety symptoms were: moderate-to-severe depressive symptoms (AOR: 26.10, 95% CI: 8.10-84.15, p <0.001), attending a public academic institution (AOR: 3.33, 95% CI: 1.14-10.00, p = 0.028), and boarding school history (AOR: 4.35, 95% CI: 1.14-16.67, p = 0.032). YSMM in Nairobi experience a high burden of depressive and anxiety symptoms with substantial co-occurrence. Living with HIV, experiencing healthcare-related discrimination and educational context play key roles in shaping mental health outcomes among YSMM. These findings underscore the importance of integrating mental health with HIV services, alongside stigma-reduction interventions in both healthcare and educational settings, to improve access, quality of care, and outcomes for this young key population.

  • Open Access

    HPV acquisition and clearance in women randomized to the contraceptives depot medroxyprogesterone acetate, copper intrauterine device, or levonorgestrel implant: a secondary analysis of a randomized clinical trial

    by Anna-Ursula Happel, Smritee Dabee, Elvira Budiawan, Maricianah Onono, Steve Innes, Thesla Palanee-Phillips, Joan Ongere, Imeldah Wakhungu, Zandile Mkhize, La-Donna Kapa, et al.

  • Open Access

    Context Matters: Urban Typology and Pandemic‐Related Mental Health Decline in Low‐Income South African Settings

    by Maretha Visser, Rhena Delport, Ariane Neethling, Edith Madela‐Mntla, David Everatt, Thesla Palanee‐Phillips, Tobias Barnard, Jannie Hugo

    Aim: We explored the negative impact of the COVID‐19 pandemic on self‐reported mental health and perceived social and economic challenges in very‐low‐ to low‐ to middle‐income households in four urban typologies in South Africa: formal township dwellings, backyard dwellings, inner‐city high‐density apartments, and informal settlement dwellings. The purpose was to inform urban policy and crisis‐response planning. Methods: Structured interviews were conducted with 1330 adults from a stratified random sample from each urban typology during the third SARS‐CoV‐2 wave. Results: Respondents reported increases in anxiety (28.5%), depression (23.9%), and decreased social connectedness (20.0%). Conversely, some respondents reported improved mental health, with decreases in anxiety (16.3%), depression (18.4%), and increased social connectedness (17.5%). Anxiety and depression were more prevalent in formal township dwellings and high‐density apartments than in informal settlements. Financial concerns, worries about isolation, crime, and community violence, and fear of COVID‐19 infection and stigma were mostly associated with decreased mental health. Conclusions: Our findings suggest that residents from different urban typologies were affected differently by the COVID‐19 pandemic. This research demonstrates the impact of environmental disasters on mental health in urban communities, which is mediated by social and economic problems.


  • Open Access

    Association of human papillomavirus on risk of HIV acquisition in African women: analyses from MTN-020/ASPIRE

    by Christine L Hathaway, Elizabeth R Brown, Stephen Cherne, Alyssa L Sepulveda, Zvavahera M Chirenje, Nitesha Jeenarain, Logashvari Naidoo, Samantha Siva, Nishanta Singh, Kubashni Woeber, et al.

    Background: Observational data on the synergy between human papillomavirus (HPV) infection and risk for HIV acquisition are needed. HPV clearance, associated with an influx of cells targeted by HIV, may increase HIV risk. This study examined the association between HPV and HIV acquisition using endocervical swabs collected in MTN-020/ASPIRE. Methods: Healthy, sexually active women without HIV participating in the ASPIRE dapivirine ring study in Malawi, South Africa, Uganda, and Zimbabwe provided endocervical swabs monthly, which were tested for HPV-DNA. HPV status was classified into prevalent, persistent (HPV+ for at least 4 months), HPV clearance (HPV+ followed by HPV−), HPV acquisition (HPV− followed by HPV+), and remaining HPV positive (2 subsequent HPV+). Cox time-varying regression models were used to assess associations between HPV states and HIV acquisition. Results: Among 91 HIV acquisition endpoints, HPV clearance increased HIV risk for high-risk types (16/18/31/33/35/45/52/58) (HR = 2.40, 95% CI = 1.59 to 3.62). Remaining HPV+ also showed a moderately increased risk (HR = 1.59, 95% CI = 1.07 to 2.35), while prevalent, persistent, and HPV acquisition events showed non-significant associations. Elevated HIV risk was also observed for clearance of HPV16/18, other high-risk types, low-risk types, and HPV6/11. There was also a dose-response relationship, with HIV risk increasing by 1.75-fold (95% CI = 1.55 to 1.96) for each additional HPV type cleared. Conclusions: HPV clearance-related immune activation is strongly linked to HIV acquisition, likely due to increased CD4+ T cells and inflammation. These findings support HPV vaccination as a potential HIV prevention strategy and highlight the need to integrate HIV prevention into cervical cancer programs.


  • Open Access

    Validation of Rapid Point-of-Care Diagnostic Tests for Sexually Transmitted Infection Self-Testing Among Adolescent Girls and Young Women

    by Krishnaveni Reddy, Jiaying Hao, Nompumelelo Sigcu, Merusha Govindasami, Nomasonto Matswake, Busisiwe Jiane, Reolebogile Kgoa, Lindsay Kew, Nkosiphile Ndlovu, Reginah Stuurman, et al.

    Background/Objectives: High rates of sexually transmitted infections (STIs) increase HIV transmission risk among adolescent girls and young women (AGYW) in South Africa. AGYW prefer discreet self-testing options for HIV and pregnancy; however, other STI self-testing options are currently unavailable in this region. Methods: Seven Chlamydia trachomatis (CT), Neisseria gonorrhea (NG) and Trichomonas vaginalis (TV) assays were validated for AGYW self-test use (using self-collected vaginal samples) in a cross-sectional study (PROVE). Paired GeneXpert® NG/CT (Cepheid®, Sunnyvale, CA, USA) and OSOM® Trichomonas test (Sekisui Diagnostics, Burlington, MA, USA) results from nurse-collected samples served as reference results to calculate sensitivity, specificity, positive predictive values (PPV), and negative predictive values (NPV). One test, the polymerase chain reaction (PCR)-based Visby Medical™ Sexual Health Test device (Visby Medical™, San Jose, CA, USA), was validated for accuracy of positive test results using self-collected samples and home-based testing in a longitudinal follow-up study enrolling AGYW aged 16–18 years. Paired GeneXpert® NG/CT and TV results from nurse-collected vaginal samples served as reference tests. Results: In PROVE, 146 AGYW contributed 558 paired samples. The Visby Medical™ Sexual Health Test exhibited moderate to high sensitivity (66.7–100%), specificity (80–100%), NPV (66.7–100%), and PPV (66.7–100%) for NG, CT, and TV. The remaining tests’ performances were markedly lower. In the longitudinal study, 28 AGYW contributed 84 paired samples, and the Visby Medical™ Sexual Health Test demonstrated 100% accuracy of positive results for CT, NG, and TV. Conclusions: The Visby Medical™ Sexual Health Test demonstrated high reliability as a potential option for AGYW to discreetly self-test for multiple STIs concurrently. Testing of its acceptability, utility, and feasibility in a larger sample of AGYW is in progress.


  • Pharmacokinetic and Clinical Associations Between Doravirine-Containing Antiretroviral Therapy and Injectable and Implantable Hormonal Contraceptive Methods Among Women Living With Human Immunodeficiency Virus in South Africa

    by Rena C Patel, Nkosiphile Ndlovu, Pooja Maheria, Reolebogile Kgoa, Lindsay Kew, La-Donna Kapa, Krishnaveni Reddy, Merusha Govindasami, Nomasonto Matswake, Nompumelelo Sigcu, et al.

    Background: Drug resistance and intolerance of dolutegravir-containing antiretroviral therapy (ART) are rising in low- and middle-income countries, resulting in a potentially increased use of doravirine-containing ART use. There are knowledge gaps regarding doravirine and hormonal contraceptive drug–drug interactions among women living with human immunodeficiency virus (HIV). Methods: We conducted a 5-parallel-group, prospective pharmacokinetic study among women living with HIV aged 18–45 years in Johannesburg, South Africa, between November 2021 and February 2024. We included a sixth, historical comparator group from a Kenyan study. After a ≥6-week lead-in period with doravirine-containing ART, participants initiated injectable medroxyprogesterone acetate (MPA), implantable etonogestrel (ENG), or nonhormonal intrauterine device contraception and were observed every 2–4 weeks for an additional 12 or 24 weeks. We analyzed serum MPA and ENG and plasma doravirine or dolutegravir concentrations per visit, using validated liquid chromatography–mass spectrometry assays. We assessed log-transformed concentrations of each drug with geometric mean ratios (90% confidence intervals) and a multivariate model adjusted for age and body mass index. We described safety, tolerability, and effectiveness (HIV RNA <40 copies/mL) of doravirine-containing ART. Results: A total of 128 participants are included in this analysis. There were no significant reductions in the MPA, ENG, or doravirine concentrations. A total of 8 (3%) adverse events grade ≥2 were considered attributable to doravirine-containing ART and 22 (8%) to the contraceptive method. ART satisfaction was 100%, and viral suppression at study exit ranged from 86% to 96%. Conclusions: We found no detrimental bidirectional drug–drug interactions and few adverse events between doravirine and hormonal contraceptives.

  • Open Access

    True and False Positive HIV Point of Care Test Results in a Prospective Multinational Study of At-Risk African Women: Implications for Large-Scale Repeat HIV Testing in HIV Prevention Programs

    by Susan Morrison, Joanne Batting, Valentine Wanga, Ivana Beesham, Jennifer Deese, G. Justus Hofmeyr, Margaret Phiri Kasaro, Cheryl Louw, Charles S. Morrison, Nelly R. Mugo, et al.

    Background: Accurate HIV point of care testing is the cornerstone of prevention and treatment efforts globally, although false (both negative and positive) results are expected to occur. Setting: We assessed the spectrum of true and false positive HIV results in a large prospective study of HIV incidence in African women using 3 contraceptive methods tested longitudinally in Eswatini, Kenya, South Africa, and Zambia. Methods: HIV serologic testing was conducted quarterly using 2 parallel rapid HIV tests. When one or both tests were positive, additional confirmatory testing was conducted, including HIV enzyme immunoassay (EIA) and RNA. Results: A total of 7730 women contributed 48,234 visits: true positive results occurred at 412 visits (0.9%) and false positives at 96 visits (0.2%). Of 412 women with HIV seroconversion, 10 had discordant (ie, 1 negative and 1 positive) rapid tests and 13 had undetectable HIV RNA levels. Of 62 women with false positive rapid HIV results, most had discordant rapid testing, but 6 (9.7%) had dually positive rapid results, and 4 (6.5%) had false positive or indeterminate EIA results. The positive predictive value of dual positive rapid results was 98.3%. Conclusions: Although most rapid test results were accurate, false positive results were expected and occurred in this population of initially HIV seronegative individuals tested repeatedly and prospectively. When HIV infection occurred, not all cases had textbook laboratory results. Our findings highlight the importance of confirmatory testing, particularly for individuals undergoing repeat testing and in settings where the point prevalence is expected to be low. Trial registration: ClinicalTrials.gov number NCT02550067.